We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

CRISPR-Powered Method for Non-Invasive Blood Tests to Help Diagnose Early Stage Cancer

By LabMedica International staff writers
Posted on 02 Jun 2023
Print article
Image: A portable smartphone-based POC device for use with EXTRA-CRISPR method for cancer diagnostics (Photo courtesy of UF Health)
Image: A portable smartphone-based POC device for use with EXTRA-CRISPR method for cancer diagnostics (Photo courtesy of UF Health)

MicroRNAs, tiny RNA molecules that regulate gene expression, have been identified as potential cancer biomarkers in human fluids like blood. Extracellular vesicles, tiny particles actively discharged by cells, transfer biomolecules between cells, influencing cell functions and diseases. Tumor cells tend to release these vesicles with disease-associated microRNAs more aggressively, making them a promising source for discovering new cancer markers. However, their clinical application has been constrained due to their complexity and the absence of a tool sensitive enough for their detection. Although CRISPR technology, a potent gene-editing tool, has been increasingly recognized as a potential platform for developing new disease diagnostics, earlier CRISPR tests were not as sensitive as the gold standard RT-qPCR and involved multistep reactions with manual handling. Now, a new approach, called “EXTRA-CRISPR,” could represent a game-changing method in the microRNA testing field.

A team of researchers from University of Florida (Gainesville, FL, USA) has developed an innovative CRISPR-based strategy for non-invasive blood tests that could assist clinicians in diagnosing cancer at earlier stages. The new method, which detects microRNAs in extracellular vesicles, is as effective as the widely used RT-qPCR assays for cancer diagnosis and can be combined with a simple portable device for point-of-care clinical testing. With the aim of streamlining the complete workflow into a 'one pot' setup, the researchers created a quick, sensitive method to detect microRNAs that is simpler and reduces the risk of cross-contamination. The term 'one pot' signifies that all necessary chemical agents, except for the sample, are housed in a single test tube, and only the microRNA sample needs to be added for a reaction to carry out the analysis.

The researchers decided to tailor this technology for pancreatic cancer due to the high mortality rate associated with the disease. They demonstrated that the novel one-pot assay could be adapted for two detection methods commonly used for point-of-care testing. Using readily available components, including a blue LED illuminator, a plastic filter, and a coffee mug warmer, they first prototyped a portable smartphone-based device. These components were assembled on a 3D-printed body part, and a smartphone was attached to capture fluorescence images of the test vials post-reaction to measure the target markers. Alongside the fluorescence detector, they paired the EXTRA-CRISPR assay with a commercially available lateral-flow test strip to create an instrument-free point-of-care device. Both point-of-care methods were tested for pancreatic cancer detection, and they delivered diagnostic results consistent with those obtained with a benchtop PCR machine. A patent application has been filed by the researchers based on this work to make the one-pot CRISPR assay and the point-of-care technology widely accessible for basic research and clinical application.

“Our method is very promising for diagnosis of cancer, such as pancreatic cancer, when combined with robust microRNA biomarkers and for point-of-care testing,” said He Yan, Ph.D., a postdoctoral researcher who was part of the team. “In the future, this method can be coupled with a very simple, low-cost portable device to make pancreatic cancer detection simpler but still reliable.”

Related Links:
University of Florida 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Dengue Virus Test

Print article


Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells (Photo courtesy of Rocky Mountain Laboratories, NIAID, NIH)

AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.